证券代码：600529 证券简称：山东药玻 公告编号：2025-064 山东省药用玻璃股份有限公司 关于修订《公司章程》及拟变更法定 代表人的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担个别及连带责任。 一、 《公司章程》修订内容 根据《公司法》、《证券法》及《上市公司章程指引》等相关规定，结合公司业务发展需要，公司拟修 订《山东省药用玻璃股份有限公司章程》（以下简称"《公司章程》"）的部分条款，修订对照如下： ■ 除上述修订外，原《公司章程》其他条款内容保持不变，前述内容尚需提交公司2026年第一次临时股东 会审议，同时提请股东会授权公司管理层或其授权代表办理相关工商变更登记、章程备案等相关事宜。 经办人员可按照工商行政管理部门或其他政府有关部门提出的意见或要求，对本次修订事项进行相应调 整，授权有效期自公司股东会审议通过之日起至该等具体执行事项办理完毕之日止。具体以工商行政管 理部门登记为准。 二、变更法定代表人 基于公司长期发展战略规划及进一步加强公司经营管理的考虑，公司董事会根据公司治理的实际需求， 经公司第十一届董事会第 ...

Group 1 - Rhine Biotech plans to change control by acquiring 80% stake in Beijing Jinkangpu, with the current controlling shareholder transferring 60 million shares (8.09% of total shares) and relinquishing voting rights on 189 million shares (25.5% of total shares) [1][2] - The acquisition is expected to be completed after the transfer of shares and the board of directors' restructuring, making Guangzhou Defu Nutrition the new controlling shareholder [1] - The specific transaction price for the acquisition of Beijing Jinkangpu is yet to be determined, and the transaction is not expected to constitute a major asset restructuring [2] Group 2 - Shida Shenghua and Bertli are planning to list H-shares on the Hong Kong Stock Exchange, with both companies considering the interests of existing shareholders and market conditions [3] - The listing process for both companies is in discussion with relevant intermediaries, and specific details have not yet been finalized [3] Group 3 - Ningbo Huaxiang's subsidiary has signed a contract for the production of robot joints, which is expected to positively impact future operating performance starting from January 2026 [4] Group 4 - Ningbo Port plans to acquire 100% of the equity of Zhoushan Port Comprehensive Bonded Zone Terminal for 706 million yuan to resolve competition issues [7] - The company aims to enhance its operational capabilities through this acquisition [7] Group 5 - Huaxin Building Materials' major shareholder plans to increase its stake in the company by 200 to 400 million yuan within six months [12] - The shareholder has secured a loan commitment of up to 360 million yuan from a bank to facilitate this purchase [12]

同日，公司第十一届董事会第四次会议火速召开，推举董事张军代行董事长职责。 12月23日晚间，国内药用玻璃行业的领军者山东药玻（SH600529，股价20.07元，市值133.19亿元）发 布人事变动公告。董事长扈永刚因年龄原因申请辞去包括董事长、董事及董事会下属专门委员会在内的 所有职务。 同时，董事会会议还审议通过了修订《公司章程》以及总经理担任公司法定代表人等议案。 同样作为山东药玻老兵，张军曾任公司车间主任、分公司副经理、研发部部长、制造部部长、副总经 理，现任公司董事、总经理。前三季度营收、利润双降 回顾扈永刚任内，山东药玻稳坐国内药包材龙头宝座。根据公司2024年年度报告，公司模制瓶、棕色瓶 等核心产品销量持续增长。2024年度，公司营业收入51.25亿元。其中，核心产品"模制瓶系列"营收达 23.53亿元，毛利率达到43.26%；"棕色瓶系列"贡献11.57亿元的营收。而在2025年上半年，公司模制瓶 系列在6个月内实现了10.21亿元的营收。 此外，2024年年度报告显示，公司决定向全体股东每10股派发现金3.20元（含税），拟分配现金股利共 计2.12亿元。 根据山东药玻2025年第三季度报告 ...

证券日报网讯12月23日，山东药玻（600529）发布公告称，公司第十届职工代表团长第一次会议选举李 传林先生为公司第十一届董事会职工代表董事。 ...

证券日报网讯 12月23日，山东药玻发布公告称，公司第十一届董事会第四次会议审议通过《关于推举 董事代为履行董事长职责的议案》等多项议案。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 12月23日，山东药玻发布公告称，公司将于2026年1月8日召开2026年第一次临时股东 会。 ...

证券日报网讯 12月23日，山东药玻发布公告称，公司董事会于近日收到公司董事长扈永刚先生提交的 书面辞职报告，扈永刚先生因年龄原因申请辞去公司董事长、董事、董事会战略与可持续发展（ESG） 委员会主任委员、董事会提名委员会委员等职务，同时不再担任公司法定代表人。辞职后，扈永刚先生 将不再担任公司及其控股子公司任何职务。 （编辑 王雪儿） ...

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

证券代码：600529 证券简称：山东药玻 公告编号：2025-065 山东省药用玻璃股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2026 年 1 月 8 日 15 点 00 分 召开地点：山东省淄博市沂源县城药玻路 1 号山东药玻公司研发大楼辅楼会 议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (七) 涉及公开征集股东投票权 无 二、 会议审议事项 本次股东会审议议案及投票股东类型 股东会召开日期：2026年1月8日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (一) 股东会类型和届次 2026 年第一次临时 ...

每经AI快讯，山东药玻（SH 600529，收盘价：20.07元）12月23日晚间发布公告称，公司第十一届第四 次董事会会议于2025年12月23日在公司研发大楼六楼会议室以现场结合通讯方式召开。 2024年1至12月份，山东药玻的营业收入构成为：制造业占比90.58%，商贸服务占比8.14%，其他业务 占比1.28%。 截至发稿，山东药玻市值为133亿元。 每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 （记者 王晓波） ...